The specific aims of this proposal are focused on the continuation of the development of diphtheria toxin-related / peptide hormone fusion proteins for eukaryotic cells receptor specific targeted therapy. We have demonstrated that diphtheria toxin receptor binding domain substitution with either alpha-melanocyte stimulating hormone, or interleukin-2 sequences results in the formation of unique toxins with highly specific target cell activity. Alpha-MSH-toxin has been show to selectively cytotoxic for alpha-MSH receptor bearing malignant melanoma cells in vitro; and essentially devoid of activity for cells lacking the receptor. In a similar fashion, IL-2-toxin has been shown to be selectively toxic for high affinity IL-2 receptor bearing cells both in vitro and in vivo. Moreover, the cytotoxic action of IL-2-toxin has been show to be mediated through the IL-2 receptor, to required passage through an acidification competent vesicle, and to ADP-ribosylate the intracellular target enzyme, elongation factor 2. The biologic action of these chimeric toxins are, as anticipated, unaffected by the presence of anti-diphtheria toxin antibodies in serum. the present proposal is directed towards the further protein engineering of alpha-MSH-toxin in order to generate derivative proteins which are resistant to proteolytic degradation. Studies directed toward the continue development of Sacchromyces cerevisiae dph mutant strains as cloning and expression vehicles is also proposed. Finally, I propose the genetic construction, expression, purification, reconstitution, and in vitro studies of a second generation chimeric toxin using the alpha-subunit of the alpha / beta gonadotrophin Leuteinizing Hormone as the ligand component of a new chimeric toxin. The long term goal of these studies are centered on the development of these genetically engineered chimeric toxins as prototypes in the development of new biologicals which are targeted at specific cell surface receptors that are characteristic for selected malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA041746-06
Application #
3182504
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1986-03-01
Project End
1992-02-28
Budget Start
1991-03-01
Budget End
1992-02-28
Support Year
6
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Boston University
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02118
Jean, L F; Waters, C A; Keemy, D et al. (1993) Site-directed and deletion mutational analysis of the receptor binding domain of the interleukin-6 receptor targeted fusion toxin DAB389-IL-6. Protein Eng 6:305-11
Tatro, J B; Wen, Z; Entwistle, M L et al. (1992) Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. Cancer Res 52:2545-8
Strom, T B; Kelley, V R; Woodworth, T G et al. (1992) Interleukin-2 receptor-directed immunosuppressive therapies: antibody- or cytokine-based targeting molecules. Immunol Rev 129:131-63
Kiyokawa, T; Williams, D P; Snider, C E et al. (1991) Protein engineering of DAB-IL-2 fusion toxins to increase biologic potency. Ann N Y Acad Sci 636:331-9
Strom, T B; Anderson, P L; Rubin-Kelley, V E et al. (1991) Immunotoxins and cytokine toxin fusion proteins. Ann N Y Acad Sci 636:233-50
Landgraf, B E; Williams, D P; Murphy, J R et al. (1991) Conformational perturbation of interleukin-2: a strategy for the design of cytokine analogs. Proteins 9:207-16
Kiyokawa, T; Williams, D P; Snider, C E et al. (1991) Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells. Protein Eng 4:463-8
Lakkis, F; Steele, A; Pacheco-Silva, A et al. (1991) Interleukin 4 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein. Eur J Immunol 21:2253-8
Jean, L F; Murphy, J R (1991) Diphtheria toxin receptor-binding domain substitution with interleukin 6: genetic construction and interleukin 6 receptor-specific action of a diphtheria toxin-related interleukin 6 fusion protein. Protein Eng 4:989-94
Wen, Z L; Tao, X; Lakkis, F et al. (1991) Diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion toxin. Internal in-frame deletion from Thr387 to His485 results in the formation of a highly potent fusion toxin which is resistant to proteolytic degradation. J Biol Chem 266:12289-93

Showing the most recent 10 out of 24 publications